According to study findings, treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone at an intended dose intensity of 80% or higher increased the risk of hospitalization for infection in a cohort of older patients with DLBCL.
“Currently, the unmet need for treatment options is high in patients with ankylosing spondylitis, including a need for effective oral treatment options following NSAIDs and a need for additional mechanisms of action,” researchers wrote.
A new report from the Government Accountability Office casts doubt on whether insurers are abiding by federal law requiring parity in insurance coverage, which forbids health plans from passing along more of the bill for mental health care to patients than they would for medical or surgical care.
Stay in the know. Population Health Learning Network Newsletter